Interestingly, GLP-1 treatment improved postprandial hyperlipidemia, suggesting the possibility that GLP-1 administration may reduce cardiovascular disease risk in type 2 diabetes [34]. This evidence concerns the gene GLP1R and hyperlipidemia.